Ryan Kramer

Dr. Ryan Kramer

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Trends in Cardiovascular Medicine
Verified
Journal Article
Closed access
LPLauren E. Parker
Lauren E. Parker
RKRyan Kramer
Ryan Kramer
SKSamantha Kaplan
Samantha Kaplan
ALAndrew Landstrom
Andrew Landstrom

1 August 2023 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
RKRyan Kramer
Ryan Kramer
AFAmir Nima Fatahian
Amir Nima Fatahian
ACAlice Chan
Alice Chan
JMJeffery Mortenson
Jeffery Mortenson
JOJennifer Osher
Jennifer Osher
ALAndrew Landstrom
Andrew Landstrom
BACKGROUND: 1p36 deletion syndrome can predispose to pediatric-onset cardiomyopathy. Deletion breakpoints are variable and may delete the transcription factor PRDM16 . Early studies suggest that deletion of PRDM16 may underlie cardiomyopathy in patients with 1p36 deletion; however, the prognostic impact of PRDM16 loss is unknown. METHODS: This retrospective cohort included subjects with 1p36 deletion syndrome from 4 hospitals. Prevalence of cardiomyopathy and freedom from death, cardiac transplantation, or ventricular assist device were analyzed. A systematic review cohort was derived for further analysis. A cardiac-specific Prdm16 knockout mouse ( Prdm16 conditional knockout) was generated. Echocardiography was performed at 4 and 6 to 7 months. Histology staining and qPCR were performed at 7 months to assess fibrosis. RESULTS: The retrospective cohort included 71 patients. Among individuals with PRDM16 deleted, 34.5% developed cardiomyopathy versus 7.7% of individuals with PRDM16 not deleted ( P =0.1). In the combined retrospective and systematic review cohort (n=134), PRDM16 deletion-associated cardiomyopathy risk was recapitulated and significant (29.1% versus 10.8%, P =0.03). PRDM16 deletion was associated with increased risk of death, cardiac transplant, or ventricular assist device ( P =0.04). Among those PRDM16 deleted, 34.5% of females developed cardiomyopathy versus 16.7% of their male counterparts ( P =0.2). We find sex-specific differences in the incidence and the severity of contractile dysfunction and fibrosis in female Prdm16 conditional knockout mice. Further, female Prdm16 conditional knockout mice demonstrate significantly elevated risk of mortality ( P =0.0003). CONCLUSIONS: PRDM16 deletion is associated with a significantly increased risk of cardiomyopathy and cardiac mortality. Prdm16 conditional knockout mice develop cardiomyopathy in a sex-biased way. Patients with PRDM16 deletion should be assessed for cardiac disease.

25 January 2024 in HPB
Verified
Journal Article
Closed access
KRKristen E. Rhodin
Kristen E. Rhodin
SGStacy Goins
Stacy Goins
RKRyan Kramer
Ryan Kramer
AEAustin M. Eckhoff
Austin M. Eckhoff
GHGarth Herbert
Garth Herbert
MLMichael Lidsky
Michael Lidsky

7 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RKRyan Kramer
Ryan Kramer
Dimitrios MorisDimitrios Moris
Dimitrios Moris
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the ninth leading cause of cancer-related death in the United States